BTS/SIGN asthma guidance updated

1.1 million children are currently receiving treatment for asthma in the UK. | SCIENCE PHOTO LIBRARY
1.1 million children are currently receiving treatment for asthma in the UK. | SCIENCE PHOTO LIBRARY

The Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society (BTS) have updated their joint guideline on the management of asthma. The latest version includes changes to the recommended monitoring and pharmacological treatment of asthma, and a new section on asthma in adolescents.

The main changes in the pharmacological management section are as follows:

  • As CFC-based beclometasone inhalers are no longer available, doses of inhaled steroids are now referenced against HFA-propelled beclometasone. HFA-based preparations should be prescribed by brand as some are more potent than others.
  • When switching from CFC-propelled beclometasone to Qvar, the dose of beclometasone should be maintained if asthma control is poor on the CFC product but halved if control is good.
  • Long-acting β2 agonists (LABAs) should only be used in patients who are already on inhaled corticosteroids, and the inhaled corticosteroid should be continued. Combination inhalers are recommended to improve adherence and ensure that the LABA is not taken without inhaled steroid.
  • Children under specialist care may benefit from a trial of high-dose inhaled corticosteroids (greater than 800 microgram/day) before moving to oral steroids.
  • Growth should be monitored in children receiving steroids and bone mineral density should also be monitored in steroid-treated children under 5 years of age.

The new section on adolescents notes that asthma is underdiagnosed in this age group and recommends that patient inhaler preference be taken into account in order to improve adherence.

View MIMS summary

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases